Description
Dibuphelone Pharmacodynamics
Phenosanoic acid is a synthetic antioxidant of the class of space-hardened phenols. The drug stabilizes neuronal membranes by inhibiting the processes of peroxidation and changes in lipid composition of brain cell membranes. It has a neuroprotective effect. By correcting indices of microviscosity of lipid component of cell membranes it regulates adenylate cyclase and protein kinase C activity. Normalizes excitation processes in the central nervous system (CNS), has a neurotropic effect. Prevents the development of seizures, tonic extension, eliminates epileptiform activity. It improves intellectual and cognitive functions in patients with epilepsy, promotes reduction of neurological deficit and improvement of daily motor activity.
Indications
As combination therapy in patients with partial epileptic seizures with or without secondary generalization.
Contraindications
– Hypersensitivity to the components of the drug;
– marked liver function abnormalities;
– myasthenia gravis;
– severe respiratory failure (respiratory rate greater than 22/min);
– lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome;
– under 18 years of age;
– Pregnancy and breast-feeding.
Administration during pregnancy and breast-feeding
The safety of the drug Dibuphelon® during pregnancy and breastfeeding has not been studied. Do not use during pregnancy and breast feeding.
Dosage and administration method
- Capsules are taken orally with meals 2 times a day: in the morning, before 10 o’clock and in the evening, no later than 18 o’clock.
- As combination therapy in patients with partial epileptic seizures with or without secondary generalization, the recommended initial dose of the drug is 400 mg per day: 200 mg in the morning and 200 mg in the evening.
- If tolerated well, the drug dose is increased by 200 mg per day at 5-7 day intervals: first to 600 mg (400 mg in the morning and 200 mg at night) and then to 800 mg (400 mg in the morning and 400 mg at night).
- The maximum daily dose of the drug is 800 mg/day.
- The duration of therapy is determined by the attending physician.
- The drug is withdrawn gradually, reducing the dose by 200 mg per day at intervals of 5-7 days.
